Acquisition Context Körber Tissue has transitioned to Valmet as of November 2, 2023 and now operates under Valmet’s Tissue Converting business unit, signaling a corporate reorganization that may open opportunities for cross-sell or integration projects with Valmet’s existing customer base.

Growth Opportunity Revenue is estimated between 10 and 25 million USD, with a mid-sized employee base. This suggests a potential for mid-market customer outreach, after-sales service expansion, and scalable machinery upgrades or retrofits to maintain competitive performance.

Competitive Benchmark Similar companies vary widely in size and revenue; targeting peers like Pegaso and CMG could help define mid-market value propositions, price bands, and service packages that align with a comparable customer segment.

Strategic Fit As part of Valmet, there may be collaboration opportunities leveraging Valmet’s broader technology stack, aftermarket services, and global footprint to win conversions, modernization projects, or spare parts deals in tissue converting.

Sales Targeting Focus on medium-sized tissue converters seeking reliable upgrades, maintenance, and efficiency improvements; emphasize flexible service contracts, modernization of converting lines, and bundled solutions that complement Valmet’s existing offerings.